Fifteen 3-substituted analogues of steffimycin B (1) have been synthesized and their activity against P388 murine leukemia has been determined. Three of these were substantially more active than the parent compound.
Steffimycin and steffimycin B (1) were isolated some years ago,1*^and their structures were established by Wiley et alP and Arara.4) These compounds are anthracycline antibiotics, but they are unusual in this family since they do not contain an amino sugar moiety. The steffimycins have only borderline antitumor activity against P388 murine leukemia while almost all of the anthracyclines containing nitrogen are active in this assay. Experiments in our laboratory had yielded 3-iodo-l as an unexpected product. These results were interpreted to confirm that the presence of a hydroxyl group and a methoxyl group ortho to the 3 position in 1 activated that position to electrophilic substitution. This suggested ways of introducing other halogens, nitrogen-containing substituents, and other substituents at that position. Such analogues (especially the nitrogen-containing onesj might have enhanced anti-leukemic activity relative to 1. It was found that such substitution occurred, and the 3-substituent analogues de- scribed in this paper were prepared.
Chemical
Nitrogen-containing analogues of 1 were prepared in two series, carbonyl (4~6) and basic amino derivatives (7~12). It was considered that a formyl group, which could then be converted to nitrogen-containing substituents, could be introduced into position 3 by direct introduction, but this did not prove to be the case necessitating an indirect route. This route consisted of treating 1 with CH2Ounder basic conditions to prepare 2 which was then oxidized to 3. In both cases, but especially the latter, yields were poor. Oxidation was not achieved by the usual benzylic hydroxyl oxidation procedures but ret Deceased.
n Present address : The Upjohn Company, 301 Henrietta Street, Kalarnazoo, Michigan 49001, U.S.A. In ppm (<5) obtained from CDC13solutions except for 1 and 6 which were in CD3SOCD3 and CDC13-CD3OD, respectively. Trimethylsilane was the internal reference. quired pyridinium chlorochrornate. Compound3 was then converted to its carbonyl derivatives by the usual procedures. Selectivity was not a problem as the carbonyl at C-10 reacts very sluggishly with the usual carbonyl reagents. That 2 and compounds derived from it have a substituent at C-3 is shown by their XHNMRspectra. In the XHNMRspectrum of 1 chemical shifts of 8 6.75 and d 7.08 present as doublets are assigned to 3-H and 1-H. In compounds 2~5 the resonance for the higher field proton has disappeared. A singlet at <57.36~7.42 is present and must arise from 1-H. Since the 3-H proton is no longer present the substituents must be at that position. Substitution at C-3 in the other two series of compounds rests on the sameargument. The Mannich reaction was used to introduce dialkylaminomethyl groups into 1 at C-3. Compounds 7~12 were prepared in this way. Yields were poor in all cases and purification was quite difficult. In ppm (5) obtained from CDC13solutions containing trimethylsilane as internal reference. Carbon atoms in the R2ngroups are given the samenumberin both R's.
A number of other procedures for purifying these compounds other than those mentioned in the experimental were tried. None were superior to those actually used, and most were inferior.
Halogenation of 1 to give 13~16 was done by a variety of procedures differing in each case. Fluorination was done with CF3OF, chlorination with (CH3)3COC1,bromination with elemental Br2, and iodination by a periodic acid procedure similar to that of Suzuki.5) Poor analytical values were obtained for a number of these compounds. Melt solvate assay results were interpreted to indicate solvent occlusion. However, high resolution mass spectra indicated quite clearly the molecular formulas proposed.
Biological
All of the compounds prepared except 6 retained the Gram-positive antibacterial activity of 1.
The halogenated compounds and those compounds derived from 3-formyl 1 were inactive against P388 murine leukemia. However, there was considerable enhancement of the in vivo anti-leukemic activity in the case of three of the Mannich reaction products (Table 3) . While 1 has, at most, borderline activity in this assay, compounds 9, 10 and 12 showed substantial activity in the range of many of the anthracyclines containing amino sugars. For example the % T/C of daunorubicin has been reported to be 175.6'7) Experimenta l 3-Hydroxymethylsteffimycin B (2) MAR. 1988 Table 3 . Anti-leukemic activity of compounds 1~16.
Compounds {m^ffd&y) g § A solution of ll.0 g (18.7 mmol) of 1 in 250 P388 leukemia cells (106) were injected intraml of25% (CH3)3N solution was stirred at room peritoneally on day 0, and drug was injected on temp while adding dropwise 250ml of37% CH2O days *> 5 and 9-solution. The reaction mixture was heated to 80°C for 4 hours, cooled to room temp and stirred for 16 hours. The reaction mixture was evaporated in vacuo to a volume of about 300 ml. After the addition of 500 ml of H2O, the solution was adjusted to pH 6.0 with 1 n HC1 and extracted with five 250-ml portions of CH2C12 -CH3OH(9:1). The combined extracts were evaporated in vacuo to an oily residue which was dissolved in a small amount of CH2C12 -CH3OH(9 : 1) to which was added 500ml of Skellysolve B. The supernatant was decanted, and the residue was dried in vacuo. The residue was then chromatographed on 550 g of silica gel using first 3 liters of CH2C12, then 2.5 liters of CH2C12-CH3OH(95 : 5) before color appeared after which one hundred and fifty-five 20-ml fractions were collected. On the basis of TLC in CHC13-CH3OH(9: 1; Rf 0.40) fractions 1-14 and fractions 15-45 were pooled. After evaporation of the pools in vacuo there was obtained 7.51 and 4.19 g, respectively, with the second pool being pure 2. The first pool residue was chromatographed on 375 g of silica gel eluting with CH2C12 -CH3OH(95 : 5) and collecting two hundred 6-ml fractions after color appeared. Fractions 73-150 were combined as 2 on the basis of TLC as above and evaporated in vacuo, yield 1.56 g. The total yield of pure 2 was 5.75 g (49%).
Five hundred mg of the second lot of2 was dissolved in 5 ml of CH2C12. Four ml ofcyclohexane was added slowly to the boiling solution. After the mixture had stood at room temp for 24 hours it was filtered to give 381 mg; mp235~238°C; [dE +9.6°(c 0.237, CHC13); UV^?l0Hnm (e) 216 (sh, 16,685), 233 (19,900), 280 (18,240), 439 (ll,370) ; IR ymax (Nujol) cm "1 3440, 1750, 1660, 1595, 1550, 1425, 1365, 1310, 1250, 1080, 1045, 1010, 905, 860, 820, 760, 750 
3-Formylstefrlmycm B (3)
A solution of 1.04 g (4.8 mmol) of finely ground pyridinium chlorochromate in 100 ml of spectroscopic grade CH2C12was stirred, and a solution of 1.92 g (3.1 mmol) of 2 in 200 ml of spectroscopic grade CH2C12was added. The solution was stirred at room temp for 4 hours and evaporated to dryness in vacuo. The residue was dissolved in 200 ml of CH2C12-CH3OH (9 : 1), and the solution was washed with two 100-ml portions of 0.1 n HC1 and 100 ml of H2O. Evaporation in vacuo gave 1,77 g. This was chromatographed on 177 g of silica gel eluting with 800 ml of CH2C12, 900 ml of CH2C12 -CH3OH (95 : 5), 850 ml of CH2C12 -CH3OH(9 : 1) and collecting three hundred and fifty 5-ml fractions.
On the basis of TLC in CH2C12 -CH3OH-H2O (78 :20 :2; Rf 0.55) fractions 231-420 were combined and evaporated in vacuo, weight 666 mg. The residue was dissolved in a mixture of 145 ml of CH3OH-H2O (13 : 16) and acidified to pH 2 with 1.0 n HC1. The CH3OHwas removed by evaporation, and the aqueous portion was extracted with three 50-ml portions of CHC13. Evaporation in vacuo of the combined extracts gave 482 mg whose TLCin the above system showed that it was mostly 3.
One hundred and nine mg was subjected to countercurrent distribution in a 335-ml Ito Coil planetary centrifuge using the two phases of CH3C6H5-CHC13 -CH3OH-H2O (4 : 1 :4 : 1) with the upper phase being used as the stationary phase and collecting sixty 10-ml fractions. Combination of fractions 32-37 on the basis of TLCin the above system and evaporation in vacuo gave 25 mg homogeneous by TLC; mp 265-267°C (dec) (4) A mixture of200 mg (0.32 mmol) of3, 26.3 mg (0.38 mmol) ofNH2OH HC1, 45 mg of Na2CO3, 50 ml of EtOH, and 50 ml of H2O was stirred for 18 hours. The resulting solution was poured into 100 ml of H2O, and the EtOH was removed by evaporation in vacuo. The aqueous was adjusted to pH 7.5 with 0.1 n HC1 and extracted with five 50-ml portions of CHC13. The CHC13 extracts were combined and evaporated to dryness in vacuo, weight 181 mg. A portion of this (62 mg) was chromatographed on 19 g of silica gel eluting with CHC13 -CH3OH(95 : 5) to give 40 mg. This was dissolved in 10-ml of CHC13and washed with three 10-ml portions of H2O. The CHC13solution was evaporated in vacuo to give 14mg; mp 170-183°C (dec); Rf 0.12 (TLC in CHC13-CH3OH(9:1));M2D5 +128°( c 0.236, CHC13); UV ;&?!0H nm (e) 233 (20,790), 291 (16,815), 440 (7, 470) 3-Formylstefiimycin B Methoxime (5) A mixture of 200 mg (0.32 mmol) of 3, 36 mg (0.43 mmol) of CH3ONH2 HC1, 212 mg of Na2CO3 and 100ml of EtOH-H2O (1 :1) was stirred at room temp for 18 hours. The reaction mixture was poured into 100ml of H2O, and the solution was adjusted to pH 4.25 with 1 n HC1. Extraction with four 25-ml fraction portions of CHC13and evaporation in vacuo gave 181 mg of product which was chromatographed on 36 g of silica gel eluting with CHC13 -CH3OH (95 : 5) and collecting 4.5 ml fractions.
Fractions 15-24 were combined on the basis of TLC in CHC13 -CH3OH(9:1; Rf 0.44) and evaporated in vacuo. The residue was crystallized from 25 ml of EtOH to give 54 mg homogeneous by TLC; mp 108-122°C; M2D5 +13°(c 0.625, CHC13); UV^?1OH nm (e) 233 (23,860), 295 (29,410) , 439 (12,900); IR vmax (Nujol) cm "1 3480, 1705, 1670, 1610, 1570, 1460, 1370, 1255, 1190, 1030, 760 3-Formylsteffimycin B Phenylhydrazone (6) A solution of 1 ml of phenylhydrazine in 20 ml of CH3OHwas added to a solution of 200 mg MAR. 1988 (0.32mmol) of 3 in 20ml of CH3OH. One drop of CH3COOHwas added, and the solution was boiled for 12 minutes and poured into 50 ml of H2O. The mixture was extracted with four 50-ml portions of CHC13. The combined extracts were evaporated in vacuo to give 240 mg which was chromatographed on 48 g of silica gel eluting with CHC13 -CH3OH (95 : 5) and collecting one hundred and twenty 4-ml fractions.
On the basis of TLC in CHC13 -CH3OH (9 : 1; Rf 0.61) fractions 31-37 were combined and evaporated in vacuo giving 99 mg; mp 187-194°C; UV^Sl0H nm (e) 202 (32,335), 234 (32,405), 263 (25,025), 282 (22,840), 384 (14,825) , 436 (12,000); IR ymax (Nujol) cm "1 3440, 3375, 1700, 1660, 1600, 1540, 1455, 1375, 1320, 1250, 1215, 1090, 1025, 750 ; :H NMR (CDC13-CD3OD) 8 1.38 (3H, d), 1.49 (3H, s), 3.12 (1H, t), 3.62 (3H, s), 3.65 (6H, s), 3.75 (1H, d) 3-Dimethylaminomethylsteffimycin B (7) A solution of ll g (17.8 mmol) of 1 in 250 ml of26% (CH3)2NH was stirred while adding dropwise 250ml of 37% CH2O solution.
The reaction mixture was stirred at 80-85°C for 22 hours. Three hundred ml of H2O was added, and the solution was adjusted to pH 6.2 with cone HC1. The solution was extracted with five 250-ml portions of CHC13. The combined extracts were evaporated in vacuo to a weight of about 7 g which was chromatographed on 300 g of silica gel eluting with CHC13 -CH3OH (95 :5 3-Di-fl-butylaminomethylstefEmycin B (8) A solution of2 g (3.4 mmol) of 1 in 30 ml of (w-C4H9)2NH was stirred while adding dropwise 30 ml of 37% CH2O. Fifty ml of EtOH was added, and the solution was heated at 75-80°C for 68 hours. The reaction mixture was evaporated in vacuo to a black oil. This was mixed with 100 ml of ether, and 500 ml of Skellysolve B was added. The supernatant was decanted, and the residue was dried in vacuo, weight 2.38 g. The residue was chromatographed on 224 g of silica gel eluting successively with 120 ml of CHC13and 2 liters of CHC13-CH3OH(95 : 5). Those fractions containing 8 as determined by TLC in CHC13 -CH3OH(9 : 1 ; Rf 0.58) were combined and evaporated in vacuo to give 226mg; mp 119-125°C; UV ;Cl0H nm (e) 111 (18,040), 441 (17,160), 510 (sh, 3,775) ; IR ymax (Nujol) cm "1 3410, 1705, 1665, 1610, 1460, 1375, 1315, 1250, 1195, 1090, 1030, 760 Anal Calcd for C38H51NO13 : C 62.54, H 7.04, N 1.92. Found: C 61.47, H 7.14, N 1.76. 3-Pyrrolidinomethylsteffimycin B (9) A solution of 2 g (3.4 mmol) of 1 in 34 ml of pyrrolidine was stirred while adding 34 ml of 37% CH2Osolution dropwise. After the solution had been stirred at room temp for 48 hours, it was poured into 500ml of H2O, and the pH was adjusted to 7.35 with cone HC1. Extraction with five 200 ml portions of CHC13and evaporation of the combined extracts in vacuo gave 2.82 g. This material was chromatographed on 140 g of silica gel eluting with 200 ml of CHC13, 1 liter of CHC13-CH3OH (98:2), and 2.2 liters of . On the basis of TLC in CHC13-CH3OH-H2O (78 : 20 : 2; Rf 0.47) those fractions containing 9 were combined and evaporated in vacuo, yield 755 mg; mp >250°C (dec); UV^fl0H nm (e) 215 (sh, 21,570), 229 (21,910), 272 (18,655), 444 (6,105), 510 (sh, 3,725) ; IR ymax (Nujol) cm "1 3390, 1700 , 1660 , 1605 , 1450 , 1370 , 1315 , 1245 , 1185 , 1085 , 1020 ' H NMR (CDC13) 3-Piperidinomethylsteffimycin B (10) A solution of 2 g (3.4 mmol) of 1 in 55 ml of piperidine was stirred while adding dropwise 30 ml of 37%CH2Osolution. The solution was stirred at 90-95°C for 3 hours, cooled to room temp and evaporated in vacuo to about 50ml. The residue was dissolved in 100ml of ether, and 500ml of Skellysolve B was added. The supernatant was decanted, and the residue was partitioned between 200ml of CHC13and 200 ml of H2O. The CHC13layer was evaporated in vacuo, and the residue was chromatographed on 115 g of silica gel by ascending dry column chromatography eluting with 1.62 liters of CHC13 then CHC13 -CH3OH(9 : 1) obtaining 5.1 g of oily material. This was chromatographed on 50 g of silica gel eluting with EtOAc, then EtOAc -CH3OH(95 : 5), and CHC13 -CH3OH 3-Morpholinomethylsteffimycin B (ll) A solution of 2 g (3.4 mmol) of 1 in 34 ml of morpholine was stirred while adding 34 ml of 37% CH2Osolution dropwise. The solution was stirred and heated at 80-85°C for 23 hours. The reaction mixture was evaporated in vacuo to a brown oil which was chromatographed on 100 g of silica gel by dry column ascending chromatography eluting with C2H5COCH3-CH3COCH3- H2O (70 : 20 : ll) and collecting 10-ml fractions. Fractions 5-34 were combined and evaporated in vacuo. The resultant residue was dissolved in 100 ml of CH2C12to which was added 900 ml of Skellysolve B. The supernatant was decanted, and the residue (2.34 g) was chromatographed on 115 g of silica gel eluting with CHC13 -CH3COCH3 -Skellysolve B (16 :3 :4), , and CHC13 -CH3OH
(9 : 1) using 1.47 liters, 750 ml, and 200 ml, respectively. Those fractions containing ll were combined on the basis of TLC in CHC13 -CH3OH (9 : 1; Rf 0.46) and evaporated in vacuo to give 1.72 g. Two hundred mg was purified by preparative TLC in the above CHC13 -CH3OH-Skellysolve B system, yield 99 mg; mp 155-165°C (dec); UV^?1OH nm (s) 216 (24,835), 231 (25,659), 279 (22,568), 442 (12,283) ; IR vmax (Nujol) cm "1 3400, 1700, 1665, 1600, 1450, 1370, 1315, 1280, 1250, 1090, 1010, 860, 745 
3-Bromosteffimycin B (15)
A solution of 5.0 g (8.5 mmol) of1 in 50 ml ofanhydrous pyridine was stirred while adding dropwise 0.460ml (8.92mmol) of Br2. The solution was stirred at room temp for 24 hours, and 500ml of 3 n HC1was added. The resulting mixture was extracted with three 250 ml portions of CHC13-CH3OH(9 : 1). The combined extracts were evaporated in vacuo to give 5.45 g of residue. This was
